We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Destruction of Data by Clinical Trial Site Results in CRL for Dynavax Hepatitis B Drug
Destruction of Data by Clinical Trial Site Results in CRL for Dynavax Hepatitis B Drug
Dynavax announced it received an FDA complete response letter (CRL) on its sBLA for Heplisav-B vaccine because the third-party clinical trial site operator destroyed the data for approximately half the subjects.